Avatrombopag Use in Patient With Thromboembolic Risks Listed for Combined Coronary Artery Bypass Grafting and Liver Transplant: A Case Report.

Abstract

Thrombocytopenia commonly occurs in patients with advanced liver disease and can be a contraindication in patients needing combined coronary artery bypass grafting (CABG) and liver transplant (LT). Thrombopoietin receptor agonists, including avatrombopag, are part of a novel drug class and stimulate platelet production. Avatrombopag is indicated in the perioperative setting to avoid platelet transfusions, which carry several disadvantages. Avatrombopag was shown to be safe and effective in patients with chronic liver disease. This study describes the successful use of avatrombopag in a patient with thromboembolic risks in preparation for a combined CABG and LT. Larger clinical trials are necessary to validate our results.

• Authors: Bassem Almalki, Hersh Shroff, Haripriya Maddur, Juan Caicedo, Clare Kane
• Journal: Transplantation proceedings (Transplant Proc) Vol. 53 Issue 8 Pg. 2567-2569 (Oct 2021) ISSN: 1873-2623 [Electronic] United States
• PMID: 34474911 (Publication Type: Case Reports, Journal Article)
• Copyright: Copyright © 2021 Elsevier Inc. All rights reserved.

Chemical References

• Thiazoles
• Thiophenes
• avatrombopag

Topics

• Coronary Artery Bypass
• Humans
• Liver Transplantation
• Thiazoles
• Thiophenes